You are here

antitrust

Gilead, Teva reach 11th-hour settlements with some groups in HIV antitrust case

Gilead, Teva reach 11th-hour settlements with some groups in HIV antitrust case

Fierce Pharma

Gilead Sciences

Teva Pharmaceutical

Flag link:

After years of litigation, Gilead and Teva's HIV antitrust trial kicks off in California

After years of litigation, Gilead and Teva's HIV antitrust trial kicks off in California

Fierce Pharma

Gilead Sciences

Teva Pharmaceutical

Flag link:

Regeneron CEO backs FTC’s attempt to block $28B Amgen-Horizon deal

Regeneron CEO backs FTC’s attempt to block $28B Amgen-Horizon deal

Medical Marketing and Media

Horizon Therapeutics

Leonard Schleifer

Flag link:

Does FTC attempt to block Amgen's Horizon buy spell trouble for Pfizer-Seagen? Not necessarily, analysts say

Does FTC attempt to block Amgen's Horizon buy spell trouble for Pfizer-Seagen? Not necessarily, analysts say

Fierce Pharma

Horizon Therapeutics

Flag link:

Heightened US antitrust fears rattle biopharma

Heightened US antitrust fears rattle biopharma

EP Vantage

Horizon Therapeutics

Prometheus Biosciences

Flag link:

Pfizer, Seagen kick off antitrust review of $43B merger. Will FTC get on board?

Pfizer, Seagen kick off antitrust review of $43B merger. Will FTC get on board?

Fierce Pharma

Flag link:

In Zetia antitrust case, Merck and Glenmark ink deals with 2 plaintiff groups as retailers hold out

In Zetia antitrust case, Merck and Glenmark ink deals with 2 plaintiff groups as retailers hold out

Fierce Pharma

Flag link:

Sanofi's Provention buyout hit with FTC delay. Will Pfizer's Seagen deal go off as planned?

Sanofi's Provention buyout hit with FTC delay. Will Pfizer's Seagen deal go off as planned?

Fierce Pharma

Flag link:

Viatris maintains legal winning streak with yet another EpiPen antitrust victory

Viatris maintains legal winning streak with yet another EpiPen antitrust victory

Fierce Pharma

Flag link:

J&J finalizes $25M settlement, laying Remicade antitrust allegations to rest

J&J finalizes $25M settlement, laying Remicade antitrust allegations to rest

Endpoints

Flag link:

In Pfizer-Seagen review, FTC has chance to set new pharma precedent

In Pfizer-Seagen review, FTC has chance to set new pharma precedent

BioPharma Dive

anticompetitive practices

Flag link:

In antitrust suit, Hikma says Amarin locked up exclusive supply deals to shut out Vascepa generics

In antitrust suit, Hikma says Amarin locked up exclusive supply deals to shut out Vascepa generics

Fierce Pharma

Flag link:

Gilead, Teva and J&J's HIV antitrust case inches closer to trial as judge keeps most claims on the table

Gilead, Teva and J&J's HIV antitrust case inches closer to trial as judge keeps most claims on the table

Fierce Pharma

Gilead Sciences

Teva Pharmaceutical

Flag link:

Novartis, Roche avoid $475M antitrust fine in French appeals court

Novartis, Roche avoid $475M antitrust fine in French appeals court

Fierce Pharma

Flag link:

Illumina Could Face Hefty Fine Over Grail Acquisition

Illumina Could Face Hefty Fine Over Grail Acquisition

Medical Devices and Diagnostics Industry

Flag link:

Novartis to pay $245 mln to end antitrust cases over Exforge drug generics

Novartis to pay $245 mln to end antitrust cases over Exforge drug generics

Reuters

Flag link:

Is CVS' Acquisition of Signify in Danger of Falling Through?

Is CVS' Acquisition of Signify in Danger of Falling Through?

Motley Fool

Flag link:

Illumina defeats F.T.C. in major antitrust case

Illumina defeats F.T.C. in major antitrust case

NY Times, NY

Flag link:

After delay, CSL's $11.7B deal for Vifor poised to close next week

After delay, CSL's $11.7B deal for Vifor poised to close next week

Fierce Pharma

Flag link:

Can Illumina Hold on to Grail?

Can Illumina Hold on to Grail?

Medical Devices and Diagnostics Industry

Flag link:

Pages